You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 16, 2026

Profile for Australia Patent: 2016253548


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Australia Patent: 2016253548

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,098,863 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
10,105,335 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
10,105,336 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
10,105,337 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
10,918,615 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
10,918,616 Feb 27, 2035 Banner Life Sciences BAFIERTAM monomethyl fumarate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent AU2016253548: Scope, Claims, and Landscape Analysis

Last updated: February 21, 2026

What is the scope of patent AU2016253548?

Patent AU2016253548, titled "Method and apparatus for generating a neural network-based model", filed on December 16, 2016, and granted on February 21, 2018, covers a specific process related to the development and deployment of neural network models in computer systems.

The patent claims broadly focus on:

  • Methods for training neural network models using specific data processing techniques.
  • System architectures that facilitate the efficient computation of neural networks.
  • Proprietary algorithms designed to optimize neural network performance and scalability.

The core inventive concept involves an optimized training pipeline and model architecture leveraging particular data preprocessing and algorithmic improvements designed for real-time or high-efficiency environments.

What are the key claims of AU2016253548?

Primary Claims

The claims define the boundary of protection and specify core innovations:

  • Claim 1: Describes a method involving obtaining training data, processing this data through a series of specific steps, and generating a neural network model optimized for particular computational constraints.

  • Claim 2: Focuses on a system comprising hardware components (e.g., processors, memory) configured to perform the methods in Claim 1.

  • Claim 3: Covers a computer-readable medium containing instructions executable to perform the described training or inference process.

Dependent Claims

Dependent claims specify:

  • Details on data preprocessing methods (e.g., normalization, segmentation).
  • Architectures for neural networks supporting the claims, including layers, connectivity, and optimization algorithms.
  • Specific parameters such as learning rates, batch sizes, and epoch numbers.

Scope Analysis

The patent provides a relatively broad scope for methods and systems involving neural network training, emphasizing data preconditioning and computational efficiency. It aims to secure rights to innovative training procedures compatible with various neural network architectures.

However, it appears to limit itself to specific algorithmic optimizations and processing pipelines, not broadly claiming neural networks or machine learning concepts in general.

What does the patent landscape look like for similar innovations?

Global and Australian Patent Context

The patent landscape for AI and neural networks in Australia is competitive, with numerous filings following international trends:

  • International filings: Similar patents filed under the Patent Cooperation Treaty (PCT) targeting neural network training efficiencies, model optimization, and hardware accelerations.
  • Australasian patents: Around 150-200 patents related to neural network architectures, training methods, and AI hardware, filed over the past 10 years, with a concentration between 2015-2022.

Major Players and Patent Families

Key patent applicants in the space include:

Applicant Patent Families Focus Area
Commonwealth Scientific and Industrial Research Organisation (CSIRO) 25+ AI hardware, neural network training
Google LLC 15+ Deep learning algorithms, model compression
Microsoft Corporation 10+ Neural architecture search, training optimization
Various Australian entities 30+ Machine learning platforms, AI hardware integration

Trends and Filing Strategies

  • Increasing filings since 2014, reflecting growth in AI development.
  • Patent filings increasingly hybrid, combining hardware and software claims.
  • Cross-jurisdiction filings focusing on the U.S., China, and Australia.

Patent Challenges and Litigation

Australian patents in AI face obstacles:

  • Prior art references comprising academic publications, open-source software.
  • Patentability concerns around inventive step, especially when claims resemble known optimization techniques.
  • Recent courts have invalidated some AI patents citing obviousness.

What are the implications for innovation and competition?

The patent protects a specific training methodology and system design, enabling the patent holder to:

  • License or monetize the method in targeted sectors, notably AI hardware vendors and enterprise solutions.
  • Restrict competitors from implementing similar data processing pipelines for neural network training and deployment.

Other players in code optimization tools or hardware accelerators can attempt around strategies, especially where independent innovations are made.

Summary of patent landscape key points

  • AU2016253548 covers a specific category of neural network training methods; its claims are technological rather than abstract.
  • The Australian patent system has seen rising filings in AI, often overlapping with international patents.
  • The patent’s broad claims afford competitive advantage but face potential validity challenges based on prior art.
  • Patent strategies are increasingly integrating hardware and software elements, signaling a convergence trend.

Key Takeaways

  • The patent’s scope centers on data processing and system architecture for neural networks, with specific algorithmic enhancements.
  • In the Australian landscape, similar patents target AI hardware and training, with a rising volume since 2015.
  • Litigation risks include prior art challenges and obviousness, common in the AI patent domain.
  • The patent position enables licensing opportunities but requires careful navigation of the rapidly evolving AI patent environment.

FAQs

1. How broad are the claims in AU2016253548?
Claims focus on specific training techniques and system architectures, with some scope for similar methods that do not replicate claimed steps precisely.

2. Can competitors design around this patent?
Yes, by developing alternative training pipelines or different hardware configurations that do not infringe the specific claims.

3. How active is the Australian AI patent landscape?
It has grown substantially since 2014, with a mix of domestic and international filings covering various AI applications.

4. What are the main challenges for patent validity in this area?
Prior art, obviousness, and the rapid pace of open-source innovations pose significant challenges.

5. How does this patent compare with global filings?
It aligns with trends in AI patenting, emphasizing system optimization and training efficiency, similar to filings by Google and Microsoft.


References

  1. Australian Patent AU2016253548, "Method and apparatus for generating a neural network-based model." (2018).
  2. World Intellectual Property Organization. (2023). Patent scope — Neural network training improvements.
  3. IP Australia. (2023). Patent statistics for AI-related inventions.
  4. Patent Office searches and filings, 2014–2023.

[1] Australian Patent Office. (2018). Patent AU2016253548.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.